# RAW SEQUENCE LISTING PATENT APPLICATION US/08/126,505

#7

DATE: 04/01/94 TIME: 14:46:49

1 2		SEQUENCE LISTING
3 4	(1) G	eneral Information:
5 6 7	(i)	APPLICANT: Atkinson, John P.  Hourcade, Dennis  Krych, Malgorzata
8 9 10 11	(ii)	TITLE OF INVENTION: MODIFIED TRUNCATED COMPLEMENT SYSTEM REGULATORS
12 13	(iii)	NUMBER OF SEQUENCES: 11
14 15 16 17 18 19 20 21	(iv)	CORRESPONDENCE ADDRESS:  (A) ADDRESSEE: Patrea L. Pabst (B) STREET: 1100 Peachtree Street, Suite 2800 (C) CITY: Atlanta (D) STATE: Georgia (E) COUNTRY: USA (F) ZIP: 30309-4530
22 23 24 25 26 27	(v)	COMPUTER READABLE FORM:  (A) MEDIUM TYPE: Floppy disk  (B) COMPUTER: IBM PC compatible  (C) OPERATING SYSTEM: PC-DOS/MS-DOS  (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
28 29 30 31 32	(vi)	CURRENT APPLICATION DATA:  (A) APPLICATION NUMBER: US 08/126,505  (B) FILING DATE: 24-SEP-1993  (C) CLASSIFICATION:
33 34 35 36	(vii)	PRIOR APPLICATION DATA:  (A) APPLICATION NUMBER: US 07/695,514  (B) FILING DATE: 03-MAY-1991
37 38 39 40 41	(viii)	ATTORNEY/AGENT INFORMATION:  (A) NAME: Pabst, Patrea L.  (B) REGISTRATION NUMBER: 31,284  (C) REFERENCE/DOCKET NUMBER: WU101CIP
42 43 44 45 46	(ix)	TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (404)-815-6508 (B) TELEFAX: (404)-815-6555
47 48	(2) INFO	RMATION FOR SEQ ID NO:1:
49 50 51	(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 60 amino acids (B) TYPE: amino acid

# RAW SEQUENCE LISTING PATENT APPLICATION US/08/126,505

DATE: 04/01/94 TIME: 14:46:56

52		(C) STRANDEDNESS: single												
53		(D) TOPOLOGY: linear												
54														
55	(ii)	MOLECULE TYPE: protein												
56														
57	(iii)	HYPOTHETICAL: NO												
58														
59	(iv)	ANTI-SENSE: NO												
60														
61	(v)	FRAGMENT TYPE: N-terminal												
62														
63	(x)	PUBLICATION INFORMATION:												
64		(A) AUTHORS: Hourcade, D. et al.,												
65		(C) JOURNAL: J. Exp. Med.												
66		(D) VOLUME: 168												
67		(F) DAGES: 1255-1270												
68		(G) DATE: 1988												
69		(K) RELEVANT RESIDUES IN SEQ ID NO:1: FROM 1 TO 60												
70		(11)												
71	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:1:												
72	(31.1)													
73	Gln	Cys Asn Ala Pro Glu Trp Leu Pro Phe Ala Arg Pro Thr Asn Leu												
74	1	5 10 15												
7 <del>4</del> 75	_	5 10 25												
75 76	Thr	Asp Glu Phe Glu Phe Pro Ile Gly Thr Tyr Leu Asn Tyr Glu Cys												
76 77	1111	20 25 30												
		20 25 30												
78 79	7. 20	Pro Gly Tyr Ser Gly Arg Pro Phe Ser Ile Ile Cys Leu Lys Asn												
	Arg													
80		35 40 45												
81	<b>9</b>	II-1 Mary Mary Clar Ale Ive Age Avg Chig Avg Avg												
82	Ser	Val Trp Thr Gly Ala Lys Asp Arg Cys Arg Arg												
83		50 55 60												
84	(0)	DURETON FOR SEC. ID NO O												
85	(2) INFO	RMATION FOR SEQ ID NO:2:												
86		and the second of the second o												
87	(1)	SEQUENCE CHARACTERISTICS:												
88		(A) LENGTH: 60 amino acids												
89		(B) TYPE: amino acid												
90		(C) STRANDEDNESS: single												
91		(D) TOPOLOGY: linear												
92														
93	(ii)	MOLECULE TYPE: protein												
94														
95	(iii)	HYPOTHETICAL: NO												
96														
97	(iv)	ANTI-SENSE: NO												
98														
99	(v)	FRAGMENT TYPE: N-terminal												
100														
101	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:2:												
102														
		·												

# RAW SEQUENCE LISTING PATENT APPLICATION US/08/126,505

DATE: 04/01/94 TIME: 14:47:02

103	ніс	Cys	Gln.	בו∆	Dro	Δen	His	Phe	T.e.11	Phe	Δla	Lvs	T <sub>i</sub> en	Lvs	Thr	Gln
104	1	, сув	0111	AIG	5	пор	1120	1110	ncu	10		_, _		_,	15	0111
105																
106	Thr	Asn	Ala		Asp	Phe	Pro	Ile	_	Thr	Ser	Leu	Lys		Glu	Cys
107				20					25					30		
108	•		<b>~</b> 1	m		<b>a</b> 1	7	D	Dha	0	T1.	mb	C	T 0	7 ~~	7 00
109	Arg	Pro		Tyr	Tyr	GIY	Arg	40	Pne	ser	тте	1111	45	ьeu	Asp	ASII
110 111			35					40					43			
112																
113	Let	Val	Trp	Ser	Ser	Pro	Lvs	Asp	Val	Cvs	Lvs	Arq				
114		50					55			- 2	4	60				
115																
116	(2) INFO	RMAT	ION I	FOR S	SEQ :	D N	0:3:									
117																
118	(i)	_	UENC													
119			) LEI					cids								
120			) TY					۱ ــ								
121			) ST					Le								
122 123		(D	(D) TOPOLOGY: linear													
124	(ii)	MOL	ЕСПП	ድ ጥሃነ	PE: r	prote	ein									
125	(/															
126	(iii)	HYP	OTHE'	rica)	L: NO	)										
127																
128	(iv)	ANT	I-SE	NSE:	NO											
129								_								
130						T										
	(V)	FRA	GMEN'	L LA1	PE: I	v-ce.	rmına	ΣŢ								
131									. NO	. 3 .						
131 132		FRA SEQ							ои с	: 3 :						
131 132 133	(xi)	SEQ	UENC	E DES	SCRII	PTIO	N: SI	EQ II			Δan	Glv	Met	Val	His	Val
131 132 133 134	(xi) Lys		UENC	E DES	SCRII Asn	PTIO	N: SI	EQ II		Val	Asn	Gly	Met	Val		Val
131 132 133 134 135	(xi)	SEQ	UENC	E DES	SCRII	PTIO	N: SI	EQ II			Asn	Gly	Met	Val	His 15	Val
131 132 133 134 135 136	(xi) Lys 1	SEQ Ser	UENC:	E DES	SCRII Asn 5	PTIO	N: SI Pro	EQ II Asp	Pro	Val 10					15	
131 132 133 134 135	(xi) Lys 1	SEQ	UENC:	E DES	SCRII Asn 5	PTIO	N: SI Pro	EQ II Asp	Pro	Val 10					15	
131 132 133 134 135 136 137	(xi) Lys 1	SEQ Ser	UENC Cys Gly	E DES Arg Ile 20	Asn 5 Gln	PTION Pro Phe	N: SI Pro Gly	EQ II Asp Ser	Pro Gln 25	Val 10 Ile	Lys	Tyr	Ser	Cys 30	15 Thr	Lys
131 132 133 134 135 136 137 138 139 140	(xi) Lys 1	SEQ Ser	UENC Cys Gly	E DES Arg Ile 20	Asn 5 Gln	PTION Pro Phe	N: SI Pro Gly	EQ II Asp Ser	Pro Gln 25	Val 10 Ile	Lys	Tyr	Ser Ile	Cys 30	15 Thr	Lys
131 132 133 134 135 136 137 138 139 140 141	(xi) Lys 1	SEQ Ser	UENC Cys Gly	E DES Arg Ile 20	Asn 5 Gln	PTION Pro Phe	N: SI Pro Gly	EQ II Asp Ser	Pro Gln 25	Val 10 Ile	Lys	Tyr	Ser	Cys 30	15 Thr	Lys
131 132 133 134 135 136 137 138 139 140 141	(xi) Lys 1 Ile	SEQ Ser Lys	Cys Gly Arg 35	E DES Arg Ile 20 Leu	Asn 5 Gln Ile	Pro Pro Phe Gly	Pro Gly Ser	Asp Ser Ser	Pro Gln 25 Ser	Val 10 Ile Ala	Lys Thr	Tyr Cys	Ser Ile 45	Cys 30 Ile	15 Thr	Lys
131 132 133 134 135 136 137 138 139 140 141 142 143	(xi) Lys 1 Ile	SEQ Ser Lys Tyr	Cys Gly Arg 35	E DES Arg Ile 20 Leu	Asn 5 Gln Ile	Pro Pro Phe Gly	Pro Gly Ser	Asp Ser Ser	Pro Gln 25 Ser	Val 10 Ile Ala	Lys Thr	Tyr Cys Cys	Ser Ile 45	Cys 30 Ile	15 Thr	Lys
131 132 133 134 135 136 137 138 139 140 141 142 143 144	(xi) Lys 1 Ile	SEQ Ser Lys	Cys Gly Arg 35	E DES Arg Ile 20 Leu	Asn 5 Gln Ile	Pro Pro Phe Gly	Pro Gly Ser	Asp Ser Ser	Pro Gln 25 Ser	Val 10 Ile Ala	Lys Thr	Tyr Cys	Ser Ile 45	Cys 30 Ile	15 Thr	Lys
131 132 133 134 135 136 137 138 139 140 141 142 143 144	(xi) Lys 1 Ile Gly	SEQ Ser Lys Tyr	UENCI Cys Gly Arg 35 Val	Arg Ile 20 Leu Ile	Asn 5 Gln Ile	Pro Phe Gly Asp	Pro Gly Ser Asn	Asp Ser Ser	Pro Gln 25 Ser	Val 10 Ile Ala	Lys Thr	Tyr Cys Cys	Ser Ile 45	Cys 30 Ile	15 Thr	Lys
131 132 133 134 135 136 137 138 139 140 141 142 143 144	(xi) Lys 1 Ile Gly	SEQ Ser Lys Tyr	UENCI Cys Gly Arg 35 Val	Arg Ile 20 Leu Ile	Asn 5 Gln Ile	Pro Phe Gly Asp	Pro Gly Ser Asn	Asp Ser Ser	Pro Gln 25 Ser	Val 10 Ile Ala	Lys Thr	Tyr Cys Cys	Ser Ile 45	Cys 30 Ile	15 Thr	Lys
131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146	(xi) Lys 1 Ile Gly Asp	SEQ Ser Lys Tyr	UENCE Cys Gly Arg 35 Val	Arg Ile 20 Leu Ile	Asn 5 Gln Ile Trp	Pro Phe Gly Asp	Pro Gly Ser Asn 55	Asp Ser Ser 40	Pro Gln 25 Ser	Val 10 Ile Ala	Lys Thr	Tyr Cys Cys	Ser Ile 45	Cys 30 Ile	15 Thr	Lys
131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149	(xi) Lys 1 Ile Gly Asp	SEQ Ser Lys Tyr Thr 50 ORMAT SEQ (A	UENCI  Cys  Gly  Arg 35  Val  ION :	E DES Arg Ile 20 Leu Ile FOR S	Asn 5 Gln Ile Trp SEQ ARACT	Pro Phe Gly Asp ID No	Pro Gly Ser Asn 55 D:4: STICS	Asp Ser Ser 40 Glu	Pro Gln 25 Ser	Val 10 Ile Ala	Lys Thr	Tyr Cys Cys	Ser Ile 45	Cys 30 Ile	15 Thr	Lys
131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150	(xi) Lys 1 Ile Gly Asp	SEQ Ser Lys Tyr Thr 50 PRMAT SEQ (A	UENCI Cys Gly Arg 35 Val ION: UENCI LEI ) LEI	Ile 20 Leu Ile FOR S E CHANGTH PE: a	Asn 5 Gln Ile Trp SEQ : ARACT	Pro Phe Gly Asp ID No	Pro Gly Ser Asn 55 D:4: STICS	Asp Ser Ser 40 Glu	Pro Gln 25 Ser	Val 10 Ile Ala	Lys Thr	Tyr Cys Cys	Ser Ile 45	Cys 30 Ile	15 Thr	Lys
131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150	(xi) Lys 1 Ile Gly Asp	SEQ Ser Lys Tyr Thr 50 RMAT SEQ (A (B	UENC: Cys Gly Arg 35 Val ION: UENC: ) LE: ) TY: ) ST:	Ile 20 Leu Ile FOR S E CHANGTH PE: a	Asn 5 Gln Ile Trp SEQ : ARACT : 62 amino	Pro Phe Gly Asp ID NO TERIS amin	Pro Gly Ser Asn 55 D:4: STICS no acid sing	Asp Ser Ser 40 Glu	Pro Gln 25 Ser	Val 10 Ile Ala	Lys Thr	Tyr Cys Cys	Ser Ile 45	Cys 30 Ile	15 Thr	Lys
131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150	(xi) Lys 1 Ile Gly Asp	SEQ Ser Lys Tyr Thr 50 RMAT SEQ (A (B	UENCI Cys Gly Arg 35 Val ION: UENCI LEI ) LEI	Ile 20 Leu Ile FOR S E CHANGTH PE: a	Asn 5 Gln Ile Trp SEQ : ARACT : 62 amino	Pro Phe Gly Asp ID NO TERIS amin	Pro Gly Ser Asn 55 D:4: STICS no acid sing	Asp Ser Ser 40 Glu	Pro Gln 25 Ser	Val 10 Ile Ala	Lys Thr	Tyr Cys Cys	Ser Ile 45	Cys 30 Ile	15 Thr	Lys

### RAW SEQUENCE LISTING PATENT APPLICATION US/08/126,505

DATE: 04/01/94 TIME: 14:47:09

154	(ii)	MOLECULE TYPE: protein												
155 156	(iii)	HYPOTHETICAL: NO												
157 158 159	(iv)	ANTI-SENSE: NO												
160 161	(v)	FRAGMENT TYPE: N-terminal												
162 163	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:4:												
164	Lys	Ser Cys Lys Thr Pro Pro Asp Pro Val Asn Gly Met Val His Val												
165	1	5 10 15												
166														
167	Ile	Thr Asp Ile Gln Val Gly Ser Arg Ile Asn Tyr Ser Cys Thr Thr												
168		20 25 30												
169														
170	Gly	His Arg Leu Ile Gly His Ser Ser Ala Glu Cys Ile Leu Ser Gly												
171		35 40 45 .												
172														
173	Asn	Ala Ala His Trp Ser Thr Lys Pro Pro Ile Cys Gln Arg												
174		50 55 60												
175														
176	(2) INFO	RMATION FOR SEQ ID NO:5:												
177														
178	(i)	SEQUENCE CHARACTERISTICS:												
179		(A) LENGTH: 8 amino acids												
180		(B) TYPE: amino acid												
181		(C) STRANDEDNESS: single												
182		(D) TOPOLOGY: linear												
183	(::)	NOT FOUT E TUDE - markets												
184	(11)	MOLECULE TYPE: protein												
185 186	(:::\	HYPOTHETICAL: NO												
187	(111)	HIPOTRETICAL: NO												
188	(177)	ANTI-SENSE: NO												
189	(10)	ANII-SENSE. NO												
190	(37)	FRAGMENT TYPE: N-terminal												
191	( • )	INCOMENT TIES, IN COLUMNICAL												
192	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:5:												
193	(222)													
194	asp	Lys Lys Ala Pro Ile Cys Asp												
195	1	5												
196	_													
197	(2) INFO	RMATION FOR SEQ ID NO:6:												
198														
199	(i)	SEQUENCE CHARACTERISTICS:												
200		(A) LENGTH: 8 amino acids												
201		(B) TYPE: amino acid												
202		(C) STRANDEDNESS: single												
203		(D) TOPOLOGY: linear												
204														

### RAW SEQUENCE LISTING PATENT APPLICATION US/08/126,505

DATE: 04/01/94 TIME: 14:47:15

```
(ii) MOLECULE TYPE: protein
205
206
         (iii) HYPOTHETICAL: NO
207
208
         (iv) ANTI-SENSE: NO
209
210
          (v) FRAGMENT TYPE: N-terminal
211
212
          (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
213
214
           Ser Asp Pro Leu Pro Glu Cys Arg
215
216
217
     (2) INFORMATION FOR SEQ ID NO:7:
218
219
220
           (i) SEQUENCE CHARACTERISTICS:
221
                (A) LENGTH: 4 amino acids
                (B) TYPE: amino acid
222
                (C) STRANDEDNESS: single
223
224
                (D) TOPOLOGY: linear
225
226
         (ii) MOLECULE TYPE: protein
227
         (iii) HYPOTHETICAL: NO
228
229
         (iv) ANTI-SENSE: NO
230
231
          (v) FRAGMENT TYPE: N-terminal
232
233
          (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
234
235
          Ser Ser Val Gln
236
237
           1
238
239
      (2) INFORMATION FOR SEQ ID NO:8:
240
           (i) SEQUENCE CHARACTERISTICS:
241
                (A) LENGTH: 12 amino acids
242
243
                (B) TYPE: amino acid
244
                (C) STRANDEDNESS: single
                (D) TOPOLOGY: linear
245
246
          (ii) MOLECULE TYPE: protein
247
248
249
         (iii) HYPOTHETICAL: NO
250
251
         (iv) ANTI-SENSE: NO
252
253
          (v) FRAGMENT TYPE: N-terminal
254
          (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
255
```

# RAW SEQUENCE LISTING PATENT APPLICATION US/08/126,505

DATE: 04/01/94 TIME: 14:47:21

256	
257 Ser Asp Pro Leu Pro Glu Cys Arg	Ser Ser Val Gln
258 1 5	10
259	
260 (2) INFORMATION FOR SEQ ID NO:9: 261	
262 (i) SEQUENCE CHARACTERISTICS:	
263 (A) LENGTH: 12 amino acids	;
264 (B) TYPE: amino acid	
265 (C) STRANDEDNESS: single	
266 (D) TOPOLOGY: linear	
267 268 (ii) MOLECULE TYPE: protein	
269 (II) MOLECULE TIPE: protein	
270 (iii) HYPOTHETICAL: NO	
271	
272 (iv) ANTI-SENSE: NO	
273	
274 (v) FRAGMENT TYPE: N-terminal	
275	
276 (xi) SEQUENCE DESCRIPTION: SEQ I	D NO:9:
277	n ni ni ni ni
278 Ser Thr Lys Pro Pro Ile Cys Glr	
279 1 5 280	10
281 (2) INFORMATION FOR SEQ ID NO:10:	
282	
283 (i) SEQUENCE CHARACTERISTICS:	
284 (A) LENGTH: 8 amino acids	
285 (B) TYPE: amino acid	
286 (C) STRANDEDNESS: single	
287 (D) TOPOLOGY: linear	
288	
289 (ii) MOLECULE TYPE: protein	
290 291 (iii) HYPOTHETICAL: NO	
292 (111) HIPOTRETICAL. NO	
293 (iv) ANTI-SENSE: NO	
294	
295 (v) FRAGMENT TYPE: N-terminal	
296	
297	
298	
299 300 (xi) SEQUENCE DESCRIPTION: SEQ I	TD NO.10.
300 (xi) SEQUENCE DESCRIPTION: SEQ I 301	.D NO.10.
302 Gln Pro Tyr Ile Thr Gln Asn Tyr	•
303 1 5	•
304	
305 (2) INFORMATION FOR SEQ ID NO:11:	
306	

# RAW SEQUENCE LISTING PATENT APPLICATION US/08/126,505

DATE: 04/01/94 TIME: 14:47:27

307 308 309 310 311 312	(i)	(B) (C)	LEN TYI STI	NGTH PE: 8 RANDI	: 43 amino	amin cac: SS: s	no ad id sing:	cids								
313	(ii)	MOLE	CULE	TYI	PE: 3	orote	ein									
314	,				•	•										
315	(iii)	нүро	THE	CICA	L: NO	)										
316																
317	(iv)	ANTI	-SEI	ISE:	МО											
318																
319	(v)	FRAG	MEN'	TYI	PE: 1	N-te	rmina	al								
320							_									
321	(xi)	SEQU	ENCE	E DES	SCRII	PTIO	N: SI	EQ II	ONO:	:11:						
322	_,	_	_,	1	_,		_	~1		<b>.</b>	<b>G</b>	0	m1	71-	17a ]	0
323		Arg	Thr	Thr		His	Leu	GIY	Arg		Cys	ser	Thr	Ala		ser
324	1				5					10					15	
325	_				_	~ 7	~-1	_	_	<b>.</b>	<b>~</b>	77-	7 T -	***	D	7
326	Pro	Ala	Thr		Ser	GIu	GLY	ьeu		Leu	Cys	Ата	АТА		Pro	Arg
327				20					25					30		
328		_,			_	~7		_	** 1	**- 7	•					
329	Glu	Thr	_	Ата	ьeu	GIN	Pro		HIS	val	ьys					
330			35					40								
331																

# SEQUENCE VERIFICATION REPORT PATENT APPLICATION US/08/126,505

DATE: 04/01/94 TIME: 14:47:31

INPUT SET: S7711.raw

Line Error

Original Text

### SEQUENCE MISSING ITEM REPORT PATENT APPLICATION US/08/126,505

DATE: 04/01/94 TIME: 14:47:31

INPUT SET: S7711.raw

<< THERE ARE NO ITEMS MISSING >>

# SEQUENCE CORRECTION REPORT PATENT APPLICATION US/08/126,505

DATE: 04/01/94 TIME: 14:47:31

INPUT SET: S7711.raw

Line

Original Text

Corrected Text